NYSE · CTEV
Healthcare · Medical - Healthcare Information Services
$36.74
Up+$0.45 (+1.24%)
Updated Sep 11, 2026, 12:49 PM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CTEV closed at $36.74 after 20 trading sessions, down 12.98% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $35.35 | $37.77 | $35.2279 | $36.74 | 82.88K |
| Sep 9, 2026 | $37.71 | $37.71 | $35.655 | $36.29 | 119.2K |
| Sep 8, 2026 | $37.77 | $38.5806 | $36.41 | $37.71 | 94.93K |
| Sep 4, 2026 | $39.08 | $39.08 | $37.66 | $38.43 | 70.57K |
| Sep 3, 2026 | $40.46 | $42.00 | $38.52 | $39.09 | 83.85K |
| Sep 2, 2026 | $38.86 | $40.29 | $36.99 | $40.23 | 117.65K |
| Sep 1, 2026 | $39.43 | $40.82 | $38.83 | $39.35 | 134.83K |
| Aug 31, 2026 | $41.05 | $41.68 | $38.9562 | $39.83 | 139.41K |
| Aug 28, 2026 | $38.06 | $39.6463 | $37.85 | $39.39 | 132.98K |
| Aug 27, 2026 | $37.47 | $39.79 | $37.47 | $38.78 | 155.27K |
| Aug 26, 2026 | $37.58 | $37.63 | $36.855 | $37.57 | 63.91K |
| Aug 25, 2026 | $36.64 | $38.85 | $35.68 | $37.64 | 139.86K |
| Aug 24, 2026 | $37.53 | $38.3982 | $36.29 | $36.58 | 76.19K |
| Aug 21, 2026 | $34.25 | $37.34 | $34.25 | $37.27 | 199.24K |
| Aug 20, 2026 | $35.00 | $35.00 | $33.9205 | $34.08 | 94.41K |
| Aug 19, 2026 | $36.11 | $37.21 | $35.18 | $35.39 | 102.07K |
| Aug 18, 2026 | $35.02 | $36.2364 | $34.58 | $35.60 | 107.22K |
| Aug 17, 2026 | $37.28 | $38.02 | $34.76 | $35.35 | 182.68K |
| Aug 14, 2026 | $41.72 | $42.22 | $38.03 | $38.12 | 133.15K |
| Aug 13, 2026 | $35.32 | $42.47 | $35.32 | $42.22 | 223.36K |
The latest Smart Investors Daily articles mentioning CTEV.
CTEV research
Company profile and research snapshot.
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | Barclays | Overweight | — |
| Aug 12, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 10, 2026 | Citigroup | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Jul 21, 2026 | Canaccord Genuity | Buy | — |
Generated Sep 10, 2026, 9:18 PM
Claritev Corporation shares gained 1.24% today as investors digest mixed quarterly results showing improved profitability alongside concerning cash flow dynamics. The modest rally suggests the market is cautiously optimistic about the company's earnings trajectory, though underlying financial health metrics warrant closer scrutiny.
Bottom line: Claritev's earnings improvement is encouraging, but the shrinking cash position creates a concerning contradiction that investors cannot ignore. Watch closely for management's explanation of cash dynamics and guidance on when profitability will translate to positive cash generation—this will be critical for determining whether today's gain is the start of a recovery or a temporary bounce.
Yahoo · Sep 8, 2026
On August 7, Claritev Corporation (NYSE:CTEV) reported second-quarter results that beat its own targets, marking five consecutive quarters of year-over-year revenue growth. Revenue for the quarter ended June 30 climbed 6.6% to $257.5 million, and management used the momentum to raise full-year guidance for the second time this year. The number that matters most, though, […]
Fintel · Aug 28, 2026
Yahoo · Aug 27, 2026
MCLEAN, Va., August 27, 2026--Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that members of its management team will meet with investors at the following events in September 2026:
Benzinga · Aug 21, 2026
Barclays analyst Glen Santangelo maintains Claritev (NYSE:CTEV) with a Overweight and raises the price target from $28 to $40.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTEV.
